Jamie Oliver is right—this is how much fruit and veg we really should be eating every day

Artificial intelligence (AI) voice agents helped older adults with high blood pressure to accurately report their blood pressure readings and improved blood pressure management, according to preliminary research presented at the American Heart Association's Hypertension Scientific Sessions 2025 held in Baltimore, September 4–7, 2025.

Why would a suicidal teenager choose to live? It's not the kind of question most of us ever want to ask. Suicide is the third leading cause of death among 15–29-year-olds worldwide. Much of the research and media coverage still focuses on why teens might want to die. Far less often do we ask the opposite, equally urgent question: what makes life worth holding on to?

Consumption of low- and no-calorie sweeteners (LNCSs) is associated with faster cognitive decline, according to a study published online Sept. 3 in Neurology.

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs).

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase II E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations.

When it comes to the future of childhood immunizations, all eyes are on Robert F. Kennedy Jr, US Secretary of Health and Human Services, and his audacious attempt to discredit vaccinations with misinformation and dodgy "science."

What do world leaders talk about when they think we're not listening? This week it was the idea of living forever.

A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population.

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy.

A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

An analysis from the Phase III CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease.

Contaminated metal at an industrial site in Indonesia may be the source of radioactive material that led to massive recalls of imported frozen shrimp, international nuclear safety officials say, as efforts are underway to halt more U.S.-bound shipments.

It makes sense to approach some marketing efforts with skepticism. Scams, deepfakes, and deceptive social media posts are common, with people you don't know seeking to profit from your behavior.

The brain has its own waste disposal system—known as the glymphatic system—that's thought to be more active when we sleep.